Studies have implicated MECOM and/or EVI1 overexpression in increased cell proliferation, migration and reduced apoptosis, supporting MECOM’s role in ovarian cancer tumorigenesis (Bleu, 2021, Brooks, 1996, Chen, 2024, Lan, 2024, Ma, 2019, Nameki, 2023, Rockfield et al., 2019, Wang, 2021, Bard-Chapeau, 2012). This evidence concerns the gene MECOM and ovarian carcinoma.